GLP-1s and Heart Health: What the SELECT Trial Means for You

In 2023, a trial called SELECT changed how semaglutide is thought about — not as a weight-loss drug with cardiovascular side benefits, but as a drug with a proven, FDA-recognized cardiovascular risk-reduction indication in its own right. Here's what the trial actually found and why the distinction matters.

The trial: SELECT

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) was a large, randomized, placebo-controlled trial designed specifically to test whether semaglutide reduces cardiovascular events — not just body weight — in adults with established cardiovascular disease and overweight or obesity, but without diabetes². This population matters: most prior GLP-1 cardiovascular evidence came from trials in people who already had type 2 diabetes, leaving open the question of whether the benefit held in people with cardiovascular disease and obesity alone.

What it found

Published in the New England Journal of Medicine in 2023, SELECT found that semaglutide significantly reduced the rate of major adverse cardiovascular events — a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke — compared to placebo, in adults with established cardiovascular disease and overweight or obesity but without diabetes¹. This was a genuinely landmark result: it demonstrated a real reduction in hard cardiovascular outcomes, not just improvement in a risk-factor proxy like weight or blood pressure. A follow-up analysis published in Nature Medicine in 2024 additionally found favorable long-term kidney outcomes in the same trial population³, reinforcing that the drug's benefits in this population extend beyond the scale.

What changed because of it

On the strength of these results, the FDA approved a new indication for Wegovy: to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight⁴. That's a materially different, and in some ways bigger, claim than "helps you lose weight" — it means Wegovy is now approved specifically as a cardiovascular risk-reduction therapy for a defined population, alongside its weight-management indication.

Why this matters beyond the headline

Three practical consequences. First, insurance: a cardiovascular risk-reduction indication is a meaningfully different basis for coverage than "weight loss" alone, and it's part of why some payers — including, at the margins, Medicare — have started evaluating coverage for people who qualify under the cardiovascular indication specifically, separate from the weight-loss exclusion that otherwise applies; see our insurance coverage guide for how that plays out in practice. Second, it reframes who might benefit most: someone with established heart disease and obesity has a distinct, trial-proven reason to consider semaglutide beyond aesthetic or general-health weight-loss goals. Third, it's a data point worth knowing when comparing molecules — SELECT is semaglutide-specific evidence, so if cardiovascular risk reduction is part of why you're considering treatment, that's relevant to weigh alongside the broader picture in semaglutide vs. tirzepatide.

What it doesn't mean

SELECT was conducted in people who already had established cardiovascular disease — a history of heart attack, stroke, or peripheral artery disease — plus overweight or obesity. It is not evidence that semaglutide prevents heart disease from ever developing in someone with no cardiovascular history, and the FDA's indication reflects that specific population. If you don't have a cardiovascular disease diagnosis, the drug's approved rationale for you remains weight management, which still has real value but is a different claim.

The takeaway

A large, well-designed, placebo-controlled trial found semaglutide reduces cardiovascular events in adults with established heart disease and obesity or overweight — a finding significant enough to earn its own FDA indication, separate from weight loss. If cardiovascular history is part of your health picture, it's worth raising directly with a provider — see best GLP-1 provider by need for how a specific health condition like this should factor into your choice, or take the quiz to see providers matched to your priorities.